Decoding HER2 mutations and overexpression in NSCLC
Patients with advanced NSCLC driven by HER2 mutations or overexpression continue to experience aggressive disease behavior and poor outcomes. Key challenges persist, including accurately identifying HER2 aberrations, navigating the modest efficacy and toxicity of traditional treatments, and managing the high incidence of brain metastases.
As novel targeted therapies—such as ADCs, TKIs, and emerging combination strategies—offer more targeted treatment options, timely integration of these options into clinical practice is essential to improve survival and quality of life.
This program will strengthen your competency in HER2 biomarker testing to ensure accurate detection and patient selection for targeted treatments, with practical guidance to increase your confidence in the implementation, and educational activities and resources to expand your knowledge of the efficacy and safety of HER2‑targeted therapies in NSCLC patients with brain metastases.
Latest Content
Whats Next?
Case
InFocus
Apply evidence directly to patient care.
- 2 x 15 min accredited real-world case scenarios
- 0.25 AMA PRA Category 1 Credits™ each
Expert
Perspectives
Overcome challenges to implement knowledge into practice.
- 3 x 20 min interactive expert-to-expert video podcasts
Clinical
Aid
Action tools to guide at the point-of-care.
- 2 x concise clinical downloadable resources for practical application
